Hepatitis B virus (HBV) is a hepatotropic and a lymphotropic virus. An association between HBV and hematologic malignancies has been determined previously; however, the association between HBV infection and multiple myeloma (MM) remains controversial. The present study aimed to assess the prevalence of HBV infection in patients with MM, and investigate their characteristics and prognostic significance. The clinical data of 165 patients with MM who had received at least four cycles of chemotherapy between April 2008 and February 2017 at Nanjing Drum Tower Hospital (Nanjing, China) were collected. HBV markers were determined using ELISA. The rates of acute or chronic HBV infection and resolved HBV infection in patients with MM were 12.12 and 26.06%, respectively. The gain of 1q21 was significantly more prevalent in the patients who were classified as HBV-positive compared with the patients who were classified as HBV-negative (54 vs. 38.2%; P=0.048), and the level of alanine transaminase in patients who were classified as HBV-positive was significantly increased compared with the non-infected group (63.29 vs. 24.66 U/l; P=0.043). Lactate dehydrogenase, serum creatinine and serum calcium levels were additionally determined to be significant risk factors of overall survival. The progression-free survival (PFS) of patients who were classified as HBV-positive was decreased compared with patients who were classified as HBV-negative (18.97 vs. 29.67 months; P= 0.006), and being HBV-positive was determined to be an independent prognostic factor of PFS. HBV infection may contribute to MM progression through 1q21 amplification, and improved monitoring of HBV markers in patients with MM may be required.
Introduction
Hepatitis B virus (HBV) infection is a principal health problem worldwide. China has ~170 million individuals who are chronic HBV carriers, 10% of whom may develop chronic hepatitis (1) . HBV is a hepatotropic and a lymphotropic virus, and the association between HBV and hematologic malignancies, particularly B-cell non-Hodgkin lymphoma, has been described previously (2, 3) .
Multiple myeloma (MM) is the second-most common hematologic malignancy, involving malignant plasma cells that continuously proliferate in bone marrow (4) . The treatment of MM has improved since the emergence of novel therapeutics, including proteasome inhibitors, immunomodulatory drugs and CD38 antibodies, which have improved the prognosis of patients (5) . However, the etiology and pathogenesis of MM have remained unclear. MM may be associated with viral infections. Amongst the possible candidate viruses, HBV has been widely examined; however, the association between HBV infection and MM is controversial. Becker et al (6) observed that HBV infection is serologically positive in 15.8% of cases with MM and added MM to the list of potential virus-associated lymphoma entities. Teng et al (7) estimated that the prevalence of chronic HBV is 11.0% in patients with MM, and chronic hepatitis carriers exhibited poorer overall survival. However, Marcucci and Mele (3) identified that associations between HBV infection and MM are weak, as these tumors are unable to form as a consequence of the chronic antigenic stimulation of B cells.
To assess the prevalence of HBV infection and investigate the clinicopathological characteristics and prognostic significance, 165 patients with MM who had received at least four cycles of chemotherapy between April 2008 and February 2017 at Nanjing Drum Tower Hospital (Nanjing, China) were retrospectively analyzed.
Patients and methods
Patients. The diagnosis of MM was based on the criteria proposed by the International Myeloma Working Group (IMWG) (8) .
The Standard screening tests include total serum protein, serum and urine protein electrophoresis (SPEP and UPEP), immunoglobulin free light chain (FLC) in serum and bone marrow aspiration or biopsy. If a patient had monoclonal protein detected by SPEP, UPEP, or by pathological FLC ratio and the plasma cell count was ≥10%, a diagnosis of multiple myeloma was clear. A total of 306 patients with MM were diagnosed at Nanjing Drum Tower Hospital between April 2008 and February 2017. For some patients, HBV status was unavailable or they did not receive at least four cycles of chemotherapy, so they were excluded from the present analysis. Therefore, the final data file comprised 165 patients with MM to analyze the infection of HBV and assess treatment response. The patients consisted of 88 males (53.3%) and 77 females (46.7%). The median age of all the subjects was 61 years (range, 40-81 years), and their median follow-up was 28.17 months (range, 5.4-90.8 months). Univariate and multivariate analyses of overall survival (OS) and progression-free survival (PFS) were conducted. Each patient was staged by Durie-Salmon (9), International Staging System (10) and Revised-ISS (11) . The risk stratification of MM involved the IMWG risk stratification and the criteria for evaluating the therapeutic effects were in accordance with IMWG standards (12) . All the patients were continuously followed up unless patients were lost to follow-up or they had passed away. Variables regarding clinical manifestations, laboratory tests and pathological reports were retrieved from the hospital database using a medical chart review. The Ethics Committee of Nanjing University (Nanjing, China) approved the present study and written informed consent was obtained from all the patients. (13) . Chromosomal abnormalities were described, according to the International System for Human Cytogenetic Nomenclature 2013 (14) . Cytogenetic abnormalities included a minimum of two mitotic cells with a gain of the same chromosome or with the same structural abnormality and three mitotic cells with the loss of the same chromosome. CD138-purified plasma cells were analyzed through interphase fluorescence in situ hybridization (FISH) using probes for chromosomes 1q21, 13q14, immunoglobulin heavy locus (IGH) and P53 to detect the cytogenetic abnormality of MM. According to the manufacturer's protocol, CD138+ plasma cells were purified using anti-CD138 immunobeads and whole blood columns (Miltenyi Biotec GmbH). A total of 5 ml bone marrow was extracted and 50 ul of anti-CD138 immunobeads were added per ml of bone marrow, incubated at 4˚C for 15 min, centrifuged at 110 x g at 25˚C for 5 min, the supernatant was removed, and the plasma cells were separated by column. Then, the plasma cells adsorbed on the separation column were eluted with Elution buffer (Shanghai Qcbio Science & Technologies Co., Ltd.), and the purified plasma cells were hypotonicized at 25˚C for 30 min, through a 0.075 m/l potassium chloride solution, and fixed at 25˚C for 30 min by methanol/glacial acetic acid (3:1) three times and stored at ~20˚C. The probes for chromosomes 1q21, 13q14, IGH and P53 used by FISH were purchased from Beijing Jinpujia Medical Technology Co., Ltd (Beijing, China). ThermoBrite in situ hybridization (NatureGene Corp, USA) was used to perform hybridization. A minimum of 200 interphase nuclei per probe were evaluated using Olympus BX51 fluorescence microscope. The manufacturer's protocol: cell suspensions sorted by anti-CD138 immunobeads were dripped by air-dry method (15) . After baking the aged slides, they were placed in proteinase K buffer (10 µg/ml) at 45˚C for 1 to 2 h, and then washed with 2 x saline-sodium citrate solution, gradient dehydration was carried out in 70, 85 and 100% ethanol. After drying the glass slides, the prepared probes were added to the hybridizer and denatured at 75˚C for 5 min and hybridized at 42˚C for 16 h. After washing with 0.1NP-40 and 0.3-NP-40, the slides were incubated with 4,6-Diamidino-2-phenylindole (DAPI) at 25˚C for 15 min in the dark for re-staining. Then, placed the processed sample under a fluorescence microscope (magnification, x40; object lens) and randomly selected a well-dispersed area and vision of cell division to observe. The hybridization signals were observed by choosing appropriate filters according to the fluorescein labeled on the Fish probe. In each case, 200-500 cells were analyzed and the percentage of positive cells with abnormal fluorescent signal was counted. If the percentage of positive cells was greater than the threshold, the result was positive. The threshold for 1q21 amplification, deletion of 13q14 and P53 and IGH rearrangements was respectively 8.09, 9.01, 8.57, 9.19% . The data of cytogenetic analysis were from Beijing Hightrust Diagnostics (Beijing, China).
Treatment for MM. All the patients were administered at least four cycles of a regimen of chemotherapy of either bortezomib or dexamethasone; bortezomib, thalidomide and dexamethasone; or dexamethasone, cyclophosphamide, etoposide and cisplatin. A total of 16 patients received autologous stem cell transplant (ASCT) subsequent to undergoing high-dose chemotherapy. All patients with active HBV infection and chronic HBV infection received lamivudine [0.1 g once a day (qd)], entecavir (0.5 mg qd) or adefovir dipivoxil (10 mg qd) for antiviral treatment during the therapy.
Statistical analysis. SPSS 19.0 (IBM Corp., Armonk, NY, USA) was used for all statistical analyses. χ 2 tests and Fisher's exact tests were performed to compare categorical variables, and a t-test was conducted to compare numerical variables between HBV-positive (anti-HBc positive) and HBV-negative (HBsAg negative and anti-HBc negative) patients with MM. OS was defined as the time between diagnosis and mortality or last documented follow-up. PFS was calculated between the date of diagnosis and progression or mortality. Kaplan-Meier curves for OS and PFS were analyzed with a log-rank test for univariate analyses. Factors with P<0.05 in the univariate analyses were included in multivariate analysis and examined using a Cox regression model. P<0.05 was considered to indicate a statistically significant difference.
Results
Patient characteristics. Of the 165 patients with MM, 63 (38.2%) suffered from an acute or chronic HBV infection and resolved HBV infection (HBsAg or anti-HBc positive), and 102 (61.8%) did not exhibit HBV infection (Table I ). The number of patients with active, chronic or resolved HBV infection was 19 (11.51%), 24 (14.54%) and 20 (12.12%), respectively (data not shown). Furthermore, 37 patients from the whole cohort developed an extramedullary disease (EMD) at the time of diagnosis or during follow-up (Table I) . Among the subjects including HBV negative and positive patients, 74 had immunoglobulin (Ig)G type M protein (44.8%), 43 had IgA type M protein (26.1%), 36 had light chain type M protein (21.8%) and 12 had other types of M protein, including IgM, IgD and IgE (7.3%; Table I ).
According to the R-ISS, 16 .3% (27/165) of the patients were classified as stage 3 (Table I) . According to the IMWG risk stratification 15.2% (25/165) were described as low risk, 72.7% (120/165) were categorized as moderate risk and 12.1% (20/165) were recorded as high risk (Table I) . All the patients underwent at least four cycles of chemotherapy, and 49.1% (81/165) of the cases were treated with bortezomib-containing regimens (Table I ). In addition, 16 patients received ASCT following high-dosage chemotherapy.
Comparison of the clinical parameters between patients who were HBV-positive and HBV-negative. In the present study, patients classified as HBV-positive included those with an acute or chronic HBV infection and resolved HBV infection. Patients classified as HBV-negative were those who had not been infected with HBV. In Table I , the baseline characteristics, including sex, age, type of MM, DS stage, ISS stage, R-ISS stage, IMWG risk stratification, number of bone lesions, ratio of blast plasma cells, presence of EMD, therapeutic regimen and laboratory parameters, were similar among the patients regardless of their HBV status. Table II summarizes the liver-associated laboratory parameters of patients with MM. Patients classified as HBV-positive had liver dysfunction, as indicated by the increased alanine transaminase (ALT) levels (positive vs. negative; 63.29 vs. 24.66 U/l; P= 0.043; Fig. 1 ), compared with patients classified as HBV-negative. The levels of aspartate transaminase, bilirubin, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and coagulation function did not significantly differ between the two groups (P>0.05). The four chromosomal aberrations detected with FISH were as follows: i) Gain of 1q21 (44.2%); ii) deletion of 13q14 (30.3%); iii) IGH rearrangements (31.5%); and iv) deletion of P53 (17.0%; Table III ). The only significant chromosomal aberration was gain of 1q21. In total, ~54% of the patients who were classified as HBV-positive had this chromosomal aberration, which was significantly higher compared with the 38.2% of the patients who were classified as HBV-negative with the same chromosomal aberration (P=0.048; Fig. 2) . Additionally, the incidence of the three remaining chromosomal abnormalities was higher in patients classified as HBV-positive compared with patients that were HBV-negative; however, these increases were not statistically significant (P>0.05).
Summary of the six patients with HBV reactivation.
In the present study, all patients received lamivudine (0.1 g qd), entecavir (0.5 mg qd) or adefovir dipivoxil (10 mg qd) for antiviral treatment during the therapy regardless of the quantities of HBV DNA. However, six cases progressed to active infection from chronic HBV infection and the quantity of HBV DNA was >500 IU/ml in two patients (cases 2 and 4; Table IV ). In four cases, HBV reactivation developed during induction therapy and the other two cases of HBV reactivation occurred during ASCT. All patients developed the progressive disease (Table IV) .
Survival analysis.
Multiple clinical parameters were assessed to determine their association with the survival of patients with MM (Table V) . The OS of patients classified as HBV-positive was decreased compared with patients classified as HBV-negative; however, this difference was not significant (42 vs. 50 months; P>0.05; Fig. 3A ). In the univariate analyses, age, R-ISS stage, IMWG risk stratification, chromosome, ratio of blast plasma cells, β 2 -microglobulin, hemoglobin, lactate dehydrogenase (LDH), serum creatinine and serum calcium levels were identified as significant risk factors of OS (Table V; P<0.05). In the multivariate analysis, the LDH level was significantly >245 IU/l, the serum creatinine level was significantly >177 µmol/l and the serum calcium level was significantly >2.65 mmol/l (Table VI) . The PFS was significantly decreased in patients classified as HBV-positive compared with patients classified as HBV-negative (18.97 vs. 29.67 months; P=0.006; Fig. 3B ). In the univariate analyses, R-ISS stage, chromosome, EMD, stem cell transplantation, hemogloblin, LDH, serum creatinine and HBV status were identified as significant risk factors of PFS (Table V; P<0.05). The multivariate regression analysis of the PFS-influencing factors indicated that HBV-positive status and EMD were considered independent prognostic factors (Table VI) and X gene (17) . Previous studies have described lymphotropic targeting cells of peripheral blood mononuclear cells, spleen, lymph nodes, thymus and bone marrow (18, 19) . A previous retrospective case-control trial demonstrated that the HBsAg-positive rate was significantly increased in patients with MM compared with patients with acute leukemia, and HBsAg positivity may be a prognostic factor for patients with MM in HBV-endemic areas (20) . China is an area with a high incidence of HBV infection (21) . In the present study, the rates of acute and chronic HBV infection in patients with MM were 11.51 and 14.54%, respectively, which were increased compared with the prevalence of these infections in the general population (22) . Rehermann et al (23) determined that HBV is unable to be completely eradicated by the immune response, and HBsAg-negative patients may carry traces of HBV genome in their serum for decades after they clinically recover. HBV is able to replicate through an RNA intermediate, integrate into its host genome, induce genomic aberrations and instability, and remain traceable in resolved HBV infection (HBsAg negative and anti-HBc positive) (3). The deletion of 8p chromosome is an important factor in the development of HBV-associated tumors. In hepatocellular carcinoma and MM, the deletion of this chromosome has been observed in ~40% of the patients classified as HBV-positive compared with 20-30% of the patients classified as HBV-negative (24, 25) . Perhaps due to sample size, Becker et al (25) did not identify a significant difference between 1q21 amplification and the pathogenesis of MM. However, the present study identified a statistically significant gain of 1q21 between the patients classified as HBV-positive compared with the patients classified as HBV-negative. Chromodomain-helicase-DNA-binding protein 1-like (CHD1L) overexpression caused by 1q21 amplification may increase cell motility, induce filopodium formation Table III . Association of serological HBV status with chromosomal aberrations. and epithelial-mesenchymal transition, which may contribute to tumor cell invasion and metastasis (26) . The deregulated overexpression of B-cell lymphoma 9 protein (BCL9) in the pre-B leukemia cell line CEMO-1, suggested that the overexpression of BCL9 may be pathogenically essential for B-cell malignancies with breakpoints at 1q21 (27) . Therefore, it was hypothesized that HBV infection may contribute to 1q21 amplification and cause MM progression through the overexpression of CHD1L and BCL9; however, this hypothesis requires further investigation with larger cohorts. HBV infection induces B cells to produce specific antibodies that react with antigens on the surface of hepatocytes and cause liver injury, thereby increasing ALT levels (28) . Immunosuppressive chemotherapy for MM frequently induces liver dysfunction in patients infected with HBV (29) . The present data demonstrated that the level of ALT in patients with HBV infection was significantly increased compared with the non-infected group, and the level of transaminase increased in the majority of the HBsAg-positive patients prior to treatment. Therefore, monitoring the liver function of patients and timely administration of liver-protecting drugs may improve prognoses.
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Reactivation of HBV is a well-recognized complication following systemic chemotherapy for hematological malignancies. A previous study identified that Hhigh-dose therapy and ASCT were significant risk factors that were positively associated with HBV reactivation (30) . Although all the patients received lamivudine, entecavir or adefovir dipivoxil for an antiviral treatment in the present study, there were six patients with HBV reactivation. These cases received high-dose chemotherapy and two of the cases received ASCT. Therefore, it is necessary to closely monitor the HBV DNA level and antiviral therapy during high-dose chemotherapy and ASCT of patients with MM and HBV infection.
Previous studies on the association of HBV infection with the survival of patients with MM demonstrated that the OS of HBsAg-positive patients who underwent ASCT was significantly decreased compared with HBsAg-negative patients (1, 31) . The present data demonstrated that the OS of the patients classified as HBV-positive was decreased compared with the patients classified as HBV-negative; however, this difference was not significant. Therefore, these results differed from previous studies; however, this difference may be attributed to the inclusion of patients with resolved HBV infection. The LDH level was >245 IU/l, the serum creatinine level was >177 µmol/l and the serum calcium level was >2.65 mmol/l. These parameters were independent factors associated with poor prognosis. These findings were consistent with previous studies (7, 32, 33) . Therefore, an increase in LDH, serum creatinine and serum calcium levels indicated a high tumor mass, suggesting poor prognosis; however, this requires further examination. Additionally, the PFS of the patients classified as HBV-positive and patients classified as HBV-negative was evaluated subsequent to the patients undergoing chemotherapy, and the results demonstrated that the PFS was significantly shorter in the patients classified as HBV-positive. HBV infection was considered an independent prognostic factor of Cox analysis; however, this observation has yet to be demonstrated, to the best of the authors' knowledge. HBV infection promotes T-cell immunoglobulin and mucin-domain containing-3 (Tim-3) expression on Type 1 T helper cells, and T cell dysfunction mediated by the Tim-3/galectin-9 signaling pathway predicted poor prognosis in patients with HBV-associated hepatocellular carcinoma (34) . Nevertheless, whether similar mechanisms are responsible for the poor prognosis in patients classified as HBV-positive with MM requires further investigation.
In conclusion, HBV infection may contribute to MM progression through 1q21 amplification and was considered to be an independent prognostic factor among patients with MM. The close monitoring of the level of HBV markers and the timely use of antiviral drugs are crucial for HBV-positive patients.
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